Riskpilot← Back to searchSign inGet full accessKallisti Biotech AB
ABActiveOrg 5569614174Bladstigen 1Wholesale of other food · NACE 4638Est. 20140 employees
Revenue 2024
SEK 109K
-4% vs 2023
EBITDA margin
-156.4%
-569% vs 2023
Equity ratio
-241.3%
Financial strength
Net profit 2024
SEK -169K
-595% vs 2023
| Revenue | SEK 109K | -4% |
| EBITDA | SEK -170K | -569% |
| Net profit | SEK -169K | -595% |
| Total assets | SEK 18K | -88% |
| Equity | SEK -43K | -134% |
| Employees | 0 | — |
Legal name
Kallisti Biotech AB
Org number
5569614174
Legal form
Aktiebolag
NACE code
4638 · Wholesale of other food
Founded
10 februari 2014
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Import, grossistförsäljning och e-handel med kosttillskott, veterinärprodukter och kroppsvårdsprodukter för hundar, katter och hästar.
Address
Bladstigen 1
Phone
+46768858763
Email
janne@hyvaheimo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 96 | 16 | 95 | 113 | 109 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | −66 | 42 | 36 | −170 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 0 | −66 | 42 | 36 | −170 |
| Net financials | — | — | −0 | −2 | 1 |
| Profit before tax | 0 | −66 | 42 | 34 | −169 |
| Tax | −0 | −0 | — | — | — |
| Net profit | 0 | −66 | 42 | 34 | −169 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 92 | 29 | 90 | 149 | 18 |
| Equity | 90 | 25 | 67 | 126 | −43 |
| Long-term debt | 0 | 0 | — | — | 37 |
| Short-term debt | 2 | 4 | 23 | 23 | 23 |
| Total debt | 2 | 4 | 23 | 23 | 61 |
EBITDA margin
-156.4%
This company
15.8%
Market median
-1090% vs market
20202024
Equity ratio
-241.3%
This company
38.2%
Market median
-732% vs market
20202024
Return on equity
-16899900.0%
This company
18.4%
Market median
-91847383% vs market
20202024
Net profit margin
-155.7%
This company
8.1%
Market median
-2022% vs market
20202024
Asset turnover
6.08×
This company
1.12×
Market median
+443% vs market
20202024
Debt / equity
1.41×
This company
0.62×
Market median
-127% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JJ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Chairman | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Kallisti Biotech AB (this company)
Kallisti Biotech LtdKALLISTI BIOTECH LTDBoard members of Kallisti Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Janne Johan Heimonen | Chief Executive Officer | 0 companies |
| Monika Maria Nina Erlandsson | Deputy Board Member | 0 companies |
| Björn Johan Kadar | Chairman | 0 companies |
| Harriet Ruth Endean | Board of Directors | 0 companies |